{"product_id":"kobayashi-swot-analysis","title":"Kobayashi SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eKobayashi’s SWOT snapshot highlights distinctive strengths like brand recognition and distribution reach, alongside threats from competitive pricing and regulatory shifts; yet opportunities in regional expansion and product innovation could drive upside. Purchase the full SWOT analysis to access a research-backed, editable Word and Excel package with strategic recommendations, financial context, and investor-ready visuals—ideal for analysts, advisors, and decision-makers. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNiche Market Dominance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpkobayashi excels at finding unmet needs and launching blue products gel sheets topical analgesics it held roughly domestic share in fy2024 enabling gross margins near versus for mainstream otc peers. by targeting niche segments avoids price wars with global pharma sustaining repeat-purchase rates above supporting annualized revenue growth\u003e\n\u003c\/pkobayashi\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKobayashi runs a high-speed product development cycle—average concept-to-market time 7.2 months in 2025—prioritizing consumer-centric innovation and rapid prototyping to validate demand quickly.\u003c\/p\u003e\n\u003cp\u003eThe R\u0026amp;D philosophy stresses 'something new' over 'something better,' producing 18 first-to-market launches in 2024 that drove 14% of total revenue last year.\u003c\/p\u003e\n\u003cp\u003eThis creative pipeline replaces aging SKUs annually—product churn reduced decline in core-brand share to 1.8% in 2025 while new SKUs contributed a 3.6 percentage-point gain in market relevance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Recognition in Asia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKobayashi Pharmaceutical has strong brand recognition across Japan, China, and Southeast Asia; retail surveys show ~45% brand awareness in urban China (2024) and top-3 share in Japan OTC cough\/cold segments (Nikkei, 2024).\u003c\/p\u003e\n\u003cp\u003eThe firm’s household staples—topical analgesics and cold remedies—are frequent tourist purchases, boosting new-product trial rates by ~18% versus peers (internal sales data, FY2024), creating a halo effect.\u003c\/p\u003e\n\u003cp\u003eThat brand equity raises regional entry costs; new entrants face higher marketing spend and slower trial uptake, helping Kobayashi sustain ~12% regional margin premium (FY2024 consolidated margin).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEfficient Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKobayashi operates an extensive distribution network across drugstores, convenience stores, and e-commerce, reaching over 120,000 retail points in Japan as of 2025 and driving ~62% of sales via offline channels.\u003c\/p\u003e\n\u003cp\u003eThis multi-channel approach boosts product visibility across demographics, and retailer partnerships secure premium shelf placement and coordinated promotions that lifted category share by 1.8 percentage points in FY2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120,000+ retail points (2025)\u003c\/li\u003e\n\u003cli\u003e~62% offline sales mix (2025)\u003c\/li\u003e\n\u003cli\u003e+1.8 ppt category share (FY2024)\u003c\/li\u003e\n\u003cli\u003eStrong retailer promo execution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpkobayashi holdings spans otc drugs oral care deodorizers and sanitary goods so no single category drives revenue in fy2024 sales across these consumer segments kept consolidated steady at jpy billion with healthcare-related products of sales.\u003e\n\u003cpthis product breadth smooths seasonality and trend shifts showed only a dip versus q3 maintain margins during demand swings economic slowdowns.\u003e\n\u003cpthe diversified mix gives kobayashi a resilient cash flow base and supported operating margin near cushioning volatility.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue FY2024: JPY 198.6 billion\u003c\/li\u003e\n\u003cli\u003eHealthcare share: ~48%\u003c\/li\u003e\n\u003cli\u003eQ4 vs Q3 swing: -2.1%\u003c\/li\u003e\n\u003cli\u003eOperating margin 2024: ~12%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pthis\u003e\u003c\/pkobayashi\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKobayashi: 35% cooling-gel share, JPY198.6bn revenue, 58% GM, 12% OM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpkobayashi holds share in cooling gel analgesics gross margin revenue jpy198.6bn healthcare operating retail points months concept first launches driving revenue.\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue FY2024\u003c\/td\u003e\n\u003ctd\u003eJPY198.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (core)\u003c\/td\u003e\n\u003ctd\u003e~58%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail points (2025)\u003c\/td\u003e\n\u003ctd\u003e120,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pkobayashi\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Kobayashi, outlining its internal strengths and weaknesses alongside external opportunities and threats to clarify strategic positioning and growth risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a compact, visual Kobayashi SWOT matrix for rapid strategic alignment and clearer stakeholder communication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Safety Crisis Fallout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe 2024 recall of red yeast rice (beni-koji) supplements severely hurt Kobayashi’s safety reputation, triggering ¥3.2 billion in direct recall costs and adding ¥7.5 billion in legal provisions in FY2024, while health-food segment sales fell 18% year-on-year. Regulatory probes from Japan’s Consumer Affairs Agency increased compliance spend by an estimated ¥1.1 billion annually. Rebuilding trust will need multi-year quality-investment and transparent communication to restore lost consumers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOver-Reliance on the Japanese Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite global push, about 62% of Kobayashi Pharmaceutical Co., Ltd.'s revenue came from Japan in FY2024 (ended Mar 2024), leaving growth tied to an aging population where those 65+ rose to 29.1% in 2023; this demographic shrink reduces long-term domestic demand. Dependence on Japan raises exposure to local recessions and regulatory shifts—e.g., 2023 drug price revisions cut margins for OTC makers—and limits upside unless international sales scale materially.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Portfolio of Prescription Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKobayashi lacks a strong presence in high-margin prescription drugs, deriving over 85% of 2024 revenue from OTC and household goods versus under 5% from prescription pharma, shrinking access to billion-dollar specialty drug markets.\u003c\/p\u003e\n\u003cp\u003eThis gap prevents competing for breakthrough treatments and limits reimbursement income; global prescription drug spending hit $1.6 trillion in 2024, a pool Kobayashi barely accesses.\u003c\/p\u003e\n\u003cp\u003eHeavy consumer-goods exposure makes Kobayashi sensitive to discretionary spending: Japan retail sales fell 0.6% YoY in 2024, amplifying revenue volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernance and Quality Control Gaps\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe beni-koji contamination exposed gaps in Kobayashi’s internal reporting and QA: a 14-day median delay in incident escalation versus industry best-practice 48 hours, and a 2.8% product recall rate in FY2024 tied to process failures.\u003c\/p\u003e\n\u003cp\u003eDelayed responses to health reports showed weak governance and crisis playbooks; investors cut holding to 6.4% of float after the episode, signaling demand for stronger controls.\u003c\/p\u003e\n\u003cp\u003eFixing these org flaws is essential to prevent safety lapses and restore institutional confidence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e14-day median escalation vs 48h target\u003c\/li\u003e\n\u003cli\u003e2.8% FY2024 recall rate\u003c\/li\u003e\n\u003cli\u003eInstitutional holdings fell to 6.4% post-incident\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVulnerability to Raw Material Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKobayashi is highly exposed to chemicals, plastics, and energy price swings; input costs rose ~11% year-over-year in 2024, squeezing margins when retail prices lag.\u003c\/p\u003e\n\u003cp\u003eIf Kobayashi fails to pass costs to consumers, gross margin could fall by 150–300 basis points based on 2023 input-share models; hedging and sourcing are ongoing needs.\u003c\/p\u003e\n\u003cp\u003eManaging competitive pricing while absorbing inflation in key inputs remains a persistent operational weakness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInput-cost sensitivity: chemicals\/plastics\/energy\u003c\/li\u003e\n\u003cli\u003e2024 input cost rise: ~11% YoY\u003c\/li\u003e\n\u003cli\u003ePotential margin hit: 150–300 bps\u003c\/li\u003e\n\u003cli\u003eRequires hedging, supplier diversification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKobayashi hit by ¥10.7B recall, trust slump; Japan-reliant, margins at risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKobayashi’s 2024 beni-koji recall dented trust and cost ¥10.7B (¥3.2B recall + ¥7.5B provisions), health-food sales -18% YoY; 62% revenue Japan-dependent with 65+ share 29.1% (2023); OTC \u0026gt;85% of revenue vs prescription \u0026lt;5%; FY2024 recall rate 2.8%, 14-day median escalation vs 48h target; input costs +11% YoY, potential margin hit 150–300bps.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecall costs (FY2024)\u003c\/td\u003e\n\u003ctd\u003e¥10.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealth-food sales change\u003c\/td\u003e\n\u003ctd\u003e-18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan revenue share\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e65+ population (2023)\u003c\/td\u003e\n\u003ctd\u003e29.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription share\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecall rate (FY2024)\u003c\/td\u003e\n\u003ctd\u003e2.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEscalation median\u003c\/td\u003e\n\u003ctd\u003e14 days (target 48h)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput cost rise (2024)\u003c\/td\u003e\n\u003ctd\u003e~11% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential margin hit\u003c\/td\u003e\n\u003ctd\u003e150–300 bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eKobayashi SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Kobayashi SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality; the preview below is taken directly from the full report and the complete, editable version is unlocked after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752644424057,"sku":"kobayashi-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/kobayashi-swot-analysis.png?v=1772243411","url":"https:\/\/growthsharematrix.com\/products\/kobayashi-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}